wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2012 by Fudan University.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Jin Li, Fudan University
ClinicalTrials.gov Identifier:
First received: November 21, 2012
Last updated: November 26, 2012
Last verified: November 2012
The aim of this study is to compare weekly-XELIRI(wXELIRI) regimen versus FOLFIRI regimen in the treatment of advanced colorectal cancer patients. The hypothesis is the efficacy of wXELIRI is not less than FOLFIRI with tolerable toxicity.

Condition Intervention Phase
Colorectal Cancer
Drug: wXELIRI regimen
Drug: FOLFIRI regimen
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized Phase II Study of Weekly XELIRI Regimen Versus FOLFIRI in the Treatment of Advanced Colorectal Cancer Patients

Resource links provided by NLM:

Further study details as provided by Fudan University:

Primary Outcome Measures:
  • Progression free survival which is calculated from the start of treatment to disease progression or death [ Time Frame: eight weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Objective response rate which includes complete response(CR) and partial response(PR) participants [ Time Frame: eight weeks ] [ Designated as safety issue: Yes ]
    Objective response rate (ORR)= CR(complete response)+PR(partial response)

Other Outcome Measures:
  • Overall survival which is calculated from the start to treatment to the death [ Time Frame: eight months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: May 2012
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: FOLFIRI
FOLFIRI regimen
Drug: FOLFIRI regimen
irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
Other Name: FOLFIRI
Experimental: wXELIRI regimen
Drug: wXELIRI regimen
irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
Other Name: wXELIRI

Detailed Description:
The combination of irinotecan and fluorouracil drugs regimen is frequently used in patients with advanced colorectal cancer. According to the previous data, higher rate of diarrhea was observed in the combination of irinotecan and capecitabine (XELIRI) regimen, compared to the combination of irinotecan and 5-fluorouracil (FOLFIRI) regimen. However, the modified weekly XELIRI regimen, which was investigated in our previous single armed study, show tolerate toxicities compared with FOLFIRI, without compromising efficacy. It is supposed that wXELIRI regimen is no less less than FOLFIRI regimen in efficacy.

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Second-line treatment for advanced colorectal cancer,irinotecan was not previously used.
  • Age range 18-70 years old
  • ECOG performance status 0-1
  • Life expectancy of more than 3 months
  • Adequate organ function

Exclusion Criteria:

  • Previous serious cardiac disease
  • History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
  • Pregnant or lactating women
  • chronic inflammatory bowel disease or intestinal obstruction
  • Serious uncontrolled diseases and intercurrent infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01736904

Contact: Jin Li, PhD,MD 64175590-5109 fudanlijin@163.com

China, Shanghai
Fudan University Cancer Hospital Recruiting
Shanghai, Shanghai, China, 200032
Principal Investigator: Jin Li, PhD,MD         
Sponsors and Collaborators
Fudan University
Principal Investigator: Jin Lin, PhD, MD Fudan University
  More Information

Responsible Party: Jin Li, Dr, Fudan University
ClinicalTrials.gov Identifier: NCT01736904     History of Changes
Other Study ID Numbers: wXELIRI vs FOLFIRI in CRC 
Study First Received: November 21, 2012
Last Updated: November 26, 2012
Health Authority: China: Ethics Committee

Keywords provided by Fudan University:
advanced colorectal cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases

ClinicalTrials.gov processed this record on May 22, 2016